Edesa Biotech, Inc. Form 4 Filings

Nijhawan Pardeep reported acquisition or exercise transactions in this Form 4 filing.

Edesa Biotech, Inc. Chief Executive Officer and 10% owner Pardeep Nijhawan received a grant of 5,324 restricted share units on 2026-08-03, vesting in full upon grant under the 2019 Equity Incentive Compensation Plan. After this award, he directly holds 893,386 common shares, plus additional indirect holdings through affiliated entities and a family trust, for which he disclaims beneficial ownership beyond his pecuniary interest.

Nijhawan Pardeep reported acquisition or exercise transactions in this Form 4 filing.

Edesa Biotech Chief Executive Officer Pardeep Nijhawan reported a compensation-related stock grant. He received 3,378 restricted share units of Edesa Biotech common shares at no cost, which vested in full upon grant under the company’s 2019 Equity Incentive Compensation Plan.

Following this award, he directly holds 888,062 common shares. The filing also lists indirect common share holdings held through entities such as Pardeep Nijhawan Medicine Professional Corporation, 1968160 Ontario Inc., The Digestive Health Clinic Inc., and The New Nijhawan Family Trust 2015, for which he reports positions but disclaims full beneficial ownership beyond his pecuniary interest.

Edesa Biotech, Inc. Chief Executive Officer Pardeep Nijhawan acquired additional common shares in a private transaction. On June 16, 2026, he purchased 153,550 common shares at $5.21 per share, for a total of $799,995.50, and now directly holds 884,684 common shares.

He also has indirect holdings through several entities and a family trust, where he disclaims beneficial ownership beyond his pecuniary interest. These structures mean some shares are legally held by corporations and a trust associated with him rather than in his own name.

Edesa Biotech, Inc. director and Chief Executive Officer Pardeep Nijhawan reported an equity compensation award in the form of restricted share units. He received 1,671 common shares at a price of $0.0000 per share, described as a grant or award acquisition.

The filing notes these restricted share units vested in full upon grant under the company’s 2019 Equity Incentive Compensation Plan. Following this award, Nijhawan directly holds 731,134 common shares, with additional indirect holdings reported through several related entities and a family trust, subject to customary beneficial ownership disclaimers.

Marshall Patrick reported acquisition or exercise transactions in this Form 4 filing.

Edesa Biotech director Patrick Marshall received a grant of 19,000 restricted share units at no cost under the company’s 2019 Equity Incentive Compensation Plan. These units vest in equal monthly installments over twelve months starting from the grant date. After this award, he holds 71,666 common shares directly and 465 shares indirectly through Quidnet Inc.

MacDonald Sean Arthur reported acquisition or exercise transactions in this Form 4 filing.

Edesa Biotech, Inc. reported that director Sean Arthur MacDonald received a grant of 19,000 restricted share units of Common Shares on May 27, 2026 at no cost, under the company’s 2019 Equity Incentive Compensation Plan. These units vest in equal portions over twelve months starting on the grant date. Following this award, MacDonald holds 41,054 Common Shares directly.

Chypyha Joan reported acquisition or exercise transactions in this Form 4 filing.

Edesa Biotech director Joan Chypyha received 19,000 common shares as a grant of restricted share units. The award was made at a stated price of $0.00 per share, reflecting compensation rather than an open-market purchase. Following this grant, Chypyha directly owns 30,029 common shares.

The restricted share units were issued under Edesa Biotech's 2019 Equity Incentive Compensation Plan and are scheduled to vest in equal portions over twelve months starting on the grant date. This represents a routine equity compensation award for a member of the board of directors.

Weiler Peter J. reported acquisition or exercise transactions in this Form 4 filing.

Edesa Biotech, Inc. reported that its Chief Financial Officer, Peter J. Weiler, received an equity grant in the form of restricted share units. He was awarded 64,609 Common Shares at a price of $0.00 per share as a compensation-related grant, not an open‑market purchase.

The grant was issued under the company’s 2019 Equity Incentive Compensation Plan and will vest monthly in equal portions over 36 months starting on the grant date. Following this award, Weiler directly holds 129,609 Common Shares, aligning a larger portion of his pay with the company’s future share performance.

Brooks Michael J reported acquisition or exercise transactions in this Form 4 filing.

Edesa Biotech, Inc. President Michael J. Brooks reported an equity compensation award. He received 64,609 Common Shares in the form of restricted share units granted at a price of $0.00 per share under the company’s 2019 Equity Incentive Compensation Plan. These restricted share units vest monthly in equal portions over thirty-six months starting on the grant date of May 27, 2026. Following this award, Brooks directly holds a total of 291,479 Common Shares.

Sistilli Carlo reported acquisition or exercise transactions in this Form 4 filing.

Edesa Biotech, Inc. director Carlo Sistilli reported an equity grant. He received 19,000 restricted share units of Common Shares at a price of $0.00 per share under the company’s 2019 Equity Incentive Compensation Plan. These units vest in equal portions over twelve months starting on the grant date.

Following this award, Sistilli directly holds 49,417 Common Shares. Separately, 522 Common Shares are held indirectly through York-Cav Enterprises, Inc., which he partially owns and for which he disclaims beneficial ownership beyond his pecuniary interest.

Edesa Biotech director Charles V. Olson received an equity grant of 19,000 common shares on May 27, 2026. The shares were awarded at a price of $0.00 per share as a compensation grant, not an open market purchase. Following this transaction, Olson directly holds 30,000 common shares. According to the grant terms, these restricted share units will vest in equal portions over twelve months starting from the grant date, meaning the award converts into fully owned shares gradually over one year.

Nijhawan Pardeep reported acquisition or exercise transactions in this Form 4 filing.

Edesa Biotech, Inc. director and Chief Executive Officer Pardeep Nijhawan reported an equity compensation grant and updated share holdings. He received 96,913 restricted share units of common shares at $0.00 per share, issued under the company’s 2019 Equity Incentive Compensation Plan. These units vest monthly in equal portions over 36 months, beginning on the grant date, and increase his directly held common shares to 729,463.

The filing also lists indirect holdings through several entities associated with him, including shares held by 1968160 Ontario Inc., The Digestive Health Clinic Inc., Pardeep Nijhawan Medicine Professional Corporation, and The New Nijhawan Family Trust 2015, where he is co-trustee. He disclaims beneficial ownership of these indirect positions except to the extent of his pecuniary interest.

Liu Da David reported acquisition or exercise transactions in this Form 4 filing.

Edesa Biotech, Inc. reported that director Da David Liu received a grant of 19,000 Common Shares in the form of restricted share units. The award was made at a stated price of $0.00 per share, reflecting equity-based compensation rather than a market purchase.

These restricted share units were granted under the company’s 2019 Equity Incentive Compensation Plan and will vest in equal monthly installments over twelve months starting from the grant date. Following this grant, Liu directly holds 24,501 Common Shares, showing a routine increase in his equity stake tied to compensation.

Nijhawan Pardeep reported acquisition or exercise transactions in this Form 4 filing.

Edesa Biotech, Inc. director and Chief Executive Officer Pardeep Nijhawan reported an equity award and updated share holdings. He received a grant of 1,159 restricted share units that vested in full upon grant at a price of $0.0000 per share under the company’s 2019 Equity Incentive Compensation Plan, increasing his direct holdings to 632,550 common shares following the award.

Indirect holdings are reported through several entities: 402,702 common shares held by Pardeep Nijhawan Medicine Professional Corporation, 53,104 shares held by 1968160 Ontario Inc., 32,013 shares held by The Digestive Health Clinic Inc., and 32,609 shares held by The New Nijhawan Family Trust 2015. The reporting person disclaims beneficial ownership of these indirect securities except to the extent of his pecuniary interest.

Nijhawan Pardeep reported acquisition or exercise transactions in this Form 4 filing.

Edesa Biotech, Inc. reported that Chief Executive Officer Pardeep Nijhawan received a grant of 2,578 restricted share units on April 1, 2026, which vested in full upon grant under the 2019 Equity Incentive Compensation Plan. Following this award, he directly holds 631,391 common shares, with additional indirect holdings reported through several affiliated entities and a family trust.

Edesa Biotech, Inc. President Michael J. Brooks purchased 2,000 common shares in an open-market trade at $1.57 per share on February 26, 2026. Following this transaction, he directly owns 226,870 common shares, indicating a relatively small, incremental increase in his personal stake.

Edesa Biotech, Inc. Chief Executive Officer Pardeep Nijhawan reported an open-market purchase of 1,000 Common Shares on March 10, 2026 at an average price of $6.5989 per share. Following this transaction, his direct holdings increased to 628,813 Common Shares.

He also reports indirect ownership positions, including 402,702 Common Shares held by Pardeep Nijhawan Medicine Professional Corporation and additional blocks held by The New Nijhawan Family Trust 2015, The Digestive Health Clinic Inc., and 1968160 Ontario Inc. He disclaims beneficial ownership of these indirect holdings except to the extent of his pecuniary interest.

Edesa Biotech CEO-associated entity buys additional shares. On March 5, 2026, Pardeep Nijhawan Medicine Professional Corporation, an entity wholly owned by Edesa Biotech CEO and 10% owner Pardeep Nijhawan, purchased 10,000 common shares of Edesa Biotech at $3.90 per share in an open-market transaction, reported as indirect ownership.

Following this purchase, that corporation held 402,702 common shares. Nijhawan also reported 627,813 common shares held directly, plus additional indirect holdings through The New Nijhawan Family Trust 2015 and several wholly owned entities, while disclaiming beneficial ownership beyond his pecuniary interest in those indirect positions.

Edesa Biotech, Inc. director and Chief Executive Officer Pardeep Nijhawan reported an indirect open-market purchase of Common Shares. On March 4, 2026, Pardeep Nijhawan Medicine Professional Corporation, an entity wholly owned by him, bought 10,000 Common Shares at a price of $4.2560 per share. Following this transaction, that entity was reported to hold 392,702 Common Shares indirectly.

As of the same date, Nijhawan also reported 627,813 Common Shares held directly. Indirect holdings were additionally reported as 32,609 Common Shares held by The New Nijhawan Family Trust 2015, 32,013 Common Shares held by The Digestive Health Clinic Inc., and 53,104 Common Shares held by 1968160 Ontario Inc., with beneficial ownership disclaimed except to the extent of his pecuniary interest.

Edesa Biotech, Inc. director and Chief Executive Officer Pardeep Nijhawan reported an indirect open-market purchase of 10,000 common shares on March 3, 2026 at a price per share of 3.63, through Pardeep Nijhawan Medicine Professional Corporation.

The filing also reports Nijhawan’s direct and additional indirect holdings in common shares, including positions held via The New Nijhawan Family Trust 2015, The Digestive Health Clinic Inc., and 1968160 Ontario Inc., with beneficial ownership disclaimed except to the extent of his pecuniary interest.

Edesa Biotech, Inc. director and Chief Executive Officer Pardeep Nijhawan reported open-market purchases of company common shares. On March 2, 2026, he bought 2,000 common shares directly at $2.00 per share and an additional 1,000 common shares indirectly at $2.2796 per share through Pardeep Nijhawan Medicine Professional Corporation.

Following these transactions, direct holdings stood at 627,813 common shares. Indirectly, entities associated with him held 372,702 common shares at Pardeep Nijhawan Medicine Professional Corporation, 32,609 common shares at The New Nijhawan Family Trust 2015, 32,013 common shares at The Digestive Health Clinic Inc., and 53,104 common shares at 1968160 Ontario Inc. The report notes that he disclaims beneficial ownership of these indirect holdings except to the extent of his pecuniary interest.

Edesa Biotech, Inc.’s Chief Executive Officer Pardeep Nijhawan reported multiple recent transactions in the company’s common shares. He received a grant of 10,016 restricted share units that vested in full upon grant under the 2019 Equity Incentive Compensation Plan, at a stated price of $0.00 per share.

He also bought 20,571 common shares in open-market transactions at a weighted average price of $1.5789 per share and 30,000 common shares at a weighted average price of $2.2232 per share, including purchases held through Pardeep Nijhawan Medicine Professional Corporation. Additional share holdings are reported indirectly through The New Nijhawan Family Trust 2015, The Digestive Health Clinic Inc., and 1968160 Ontario Inc., with beneficial ownership disclaimed except to the extent of his pecuniary interest.

Edesa Biotech Chief Executive Officer Pardeep Nijhawan reported an equity compensation grant on common shares. On February 19, 2026, he acquired 82,236 restricted share units, which vested in full upon grant under Edesa’s 2019 Equity Incentive Compensation Plan, at a reported price of $0.00 per share. These RSUs were received in lieu of a portion of his cash bonus for the calendar year ending December 31, 2025. Following this award, Nijhawan directly owns 595,226 common shares, and additional common shares are held indirectly through entities such as Pardeep Nijhawan Medicine Professional Corporation, The New Nijhawan Family Trust 2015, The Digestive Health Clinic Inc., and 1968160 Ontario Inc., with beneficial ownership disclaimed except to the extent of his pecuniary interest.

Edesa Biotech, Inc. insider Pardeep Nijhawan, who serves as Chief Executive Officer, director, and a 10% owner, reported an equity award in the company’s common shares. On 02/02/2026, he received 11,168 restricted share units that vested in full upon grant under the 2019 Equity Incentive Compensation Plan.

Following this grant, Nijhawan is shown with 512,990 common shares held directly. Additional common shares are reported as held indirectly through entities associated with him, including Pardeep Nijhawan Medicine Professional Corporation, The New Nijhawan Family Trust 2015, The Digestive Health Clinic Inc., and 1968160 Ontario Inc., with beneficial ownership disclaimed except to the extent of his pecuniary interest.

Edesa Biotech (EDSA) reported an insider transaction by CEO, Director and 10% Owner Pardeep Nijhawan. On 11/03/2025, he acquired 6,968 common shares via a grant of restricted share units that vested in full upon grant under the company’s 2019 Equity Incentive Compensation Plan at a reported price of $0.

Following the transaction, the reporting person beneficially owned 482,612 shares directly. He also reported indirect holdings of 341,702 shares held by Pardeep Nijhawan Medicine Professional Corporation, 32,609 shares held by The New Nijhawan Family Trust 2015, 32,013 shares held by The Digestive Health Clinic Inc., and 53,104 shares held by 1968160 Ontario Inc.

Pardeep Nijhawan, Chief Executive Officer, Director and reported >10% owner of Edesa Biotech, Inc. (EDSA), received a grant of 5,908 restricted share units that vested in full upon grant on 10/02/2025 under the company's 2019 Equity Incentive Compensation Plan. The filing shows 475,644 common shares beneficially owned following the transaction, with 341,702 shares held indirectly by Pardeep Nijhawan Medicine Professional Corporation and additional indirect holdings through related entities and a family trust totaling 118,726 shares. The filing includes standard disclaimers that the reporting person disclaims beneficial ownership of certain indirect holdings except to the extent of pecuniary interest. The form was signed by an attorney-in-fact on 10/03/2025.